NAD in skin: Therapeutic approaches for niacin

Current Pharmaceutical Design

Volumn 15, Issue 1, 2009, Pages 29-38

  Benavente, Claudia A ^a   Jacobson, Myron K ^a   Jacobson, Elaine L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Actinic keratosis; NAD; Niacin; Nicotinic acid receptor; PARP; Sirtuin; Skin; Skin cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; G PROTEIN COUPLED RECEPTOR; LAURYL NICOTINATE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; NICOTINIC RECEPTOR; NUCLEAR PROTEIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN HM74A; REACTIVE OXYGEN METABOLITE; RNA POLYMERASE; SIRTUIN; SIRTUIN 6; SIRTUIN 7; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

BURNING SENSATION; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; DERMATITIS; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FLUSHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; NICOTINIC ACID DEFICIENCY; NONHUMAN; PELLAGRA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN CARCINOGENESIS; METABOLISM; SKIN; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; NAD; NIACIN; SKIN; SKIN NEOPLASMS;

EID: 62149099631     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787185760     Document Type: Review

References (126)

1. Blum H. Sunlight as a causal factor in cancer of the skin in man. J Natl Cancer Inst 1948: 247-58.
2. Emmett EA. Ultraviolet radiation as a cause of skin tumors. CRC Crit Rev Toxicol 1973; 2: 211-55.
3. Baade PD, Balanda KP, Lowe JB. Changes in skin protection behaviors, attitudes, and sunburn: In a population with the highest incidence of skin cancer in the world. Cancer Detect Prev 1996; 20: 566-75.
4. Graham S, Marshall J, Haughey B, Stoll H, Zielezny M, Brasure J, et al. An inquiry into the epidemiology of melanoma. Am J Epidemiol 1985; 122: 606-19.
5. Wolf P, Donawho CK, Kripke ML. Effect of sunscreens on UV radiation-induced enhancement of melanoma growth in mice. J Natl Cancer Inst 1994; 86: 99-105.
6. Fu CS, Swendseid ME, Jacob RA, McKee RW. Biochemical markers for assessment of niacin status in young men: Levels of erythrocyte niacin coenzymes and plasma tryptophan. J Nutr 1989; 119: 1949-55.
7. Heyes MP, Chen CY, Major EO, Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 1997; 326 (Pt 2): 351-6.
8. Benavente CA, Jacobson EL. Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes. Free Radic Biol Med 2008; 44: 527-37.
9. Warburg O, Christian W, Griese A. Wasserstoffübertragendes co-ferment, seine zusammensetsung und wirkungsweise. Biochem Z 1935; 282: 157-165.
10. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963; 11: 39-43.
11. Lange I, Penner R, Fleig A, Beck A. Synergistic regulation of endogenous TRPM2 channels by adenine dinucleotides in primary human neutrophils. Cell Calcium 2008; 44(6): 604-15.
12. Gasser A, Glassmeier G, Fliegert R, Langhorst MF, Meinke S, Hein D, et al. Activation of T cell calcium influx by the second messenger ADP-ribose. J Biol Chem 2006; 281: 2489-96.
13. Fliegert R, Gasser A, Guse AH. Regulation of calcium signalling by adenine-based second messengers. Biochem Soc Trans 2007; 35: 109-14
14. Rusinko N, Lee HC. Widespread occurrence in animal tissues of an enzyme catalyzing the conversion of NAD+ into a cyclic metabolite with intracellular Ca2+-mobilizing activity. J Biol Chem 1989; 264: 11725-31.
15. Lee HC, Walseth TF, Bratt GT, Hayes RN, Clapper DL. Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity. J Biol Chem 1989; 264: 1608-15.
16. Mandi M, Bak J. Nicotinic acid adenine dinucleotide phosphate (NAADP) and Ca2+ mobilization. J Recept Signal Transduct Res 2008; 28: 163-84
17. Berg I, Potter BV, Mayr GW, Guse AH. Nicotinic acid adenine dinucleotide phosphate (NAADP(+)) is an essential regulator of T-lymphocyte Ca(2+)-signaling. J Cell Biol 2000; 150: 581-8.
18. Vu CQ, Coyle DL, Jacobson MK. Natural occurrence of 2′-phospho-cyclic ADP ribose in mammalian tissues. Biochem Biophys Res Commun 1997; 236: 723-6.
19. Guse AH, da Silva CP, Potter BV, Mayr GW. Ca(2+)-signalling in human T-lymphocytes. Potential roles for cyclic ADP-ribose and 2′-phospho-cyclic ADP-ribose. Adv Exp Med Biol 1997; 419: 431-6.
20. Major RH. Don gasper casal, francois thiery and pellagra. Bull Hist Med 1944; 16: 351-361.
21. Spies TD. In: Joliffe N, Tisdall F, Cannon PR, Eds, Clinical nutrition. New York: PB Hoeber 1950; 531-542.
22. Bass CC. Pellagra. Medical Clinic of North America 1926; 9: 869-874.
23. Lu JY, Yu CL, Wu MZ. Pellagra in an immunocompetent patient with cytomegalovirus colitis. Am J Gastroenterol 2001; 96: 932-4.
24. Darvay A, Basarab T, McGregor JM, Russell-Jones R. Isoniazid induced pellagra despite pyridoxine supplementation. Clin Exp Dermatol 1999; 24: 167-9.
25. Castiello RJ, Lynch PJ. Pellagra and the carcinoid syndrome. Arch Dermatol 1972; 105: 574-7.
26. Rapaport MJ. Pellagra in a patient with anorexia nervosa. Arch Dermatol 1985; 121: 255-7.
27. Stevens HP, Ostlere LS, Begent RH, Dooley JS, Rustin MH. Pellagra secondary to 5-fluorouracil. Br J Dermatol 1993; 128: 578-80.
28. Jacob RA, Swendseid ME. In: Ziegler EE, Filer LJ, Eds, Present Knowledge in Nutrition. Washington, ILSI Press. 1996; 184-190.
29. Hegyi J, Schwartz RA, Hegyi V. Pellagra: Dermatitis, dementia, and diarrhea. Int J Dermatol 2004; 43: 1-5.
30. Murray MF, Langan M, MacGregor RR. Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. Nutrition 2001; 17: 654-6.
31. Pitche P, Kombate K, Tchangai-Walla K. [Prevalence of HIV infection in patients with pellagra and pellagra-like erythemas]. Med Trop (Mars) 1999; 59: 365-7.
32. Ziegler M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 2000; 267: 1550-64.
33. Hassa PO, Haenni SS, Elser M, Hottiger MO. Nuclear ADP-ribosylation reactions in mammalian cells: Where are we today and where are we going? Microbiol Mol Biol Rev 2006; 70: 789-829.
34. Jacobson MK, Jacobson EL. Discovering new ADP-ribose polymer cycles: protecting the genome and more. Trends Biochem Sci 1999; 24: 415-7.
35. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980; 283: 593-6.
36. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992; 356: 356-8.
37. Oliver FJ, Menissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease. Am J Hum Genet 1999; 64: 1282-8.
38. Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL. NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 2004; 119: 803-14.
39. Rolli V, Armin R, Augustin A, Schulz G, Menisser-de Murcia J, de Murcia G. In: Shall S, de Murcia G, Eds, Poly ADP-ribosylation reactions: From DNA damage and stress signaling to cell death. Oxford, Oxford University Press. 2000; 36-67.
40. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297: 259-63.
41. Balard B, Giacomoni PU. Nicotinamide adenosine dinucleotide level in dimethylsulfate-treated or UV-irradiated mouse epidermis. Mutat Res 1989; 219: 71-9.
42. Farzaneh F, Zalin R, Brill D, Shall S. DNA strand breaks and ADP-ribosyl transferase activation during cell differentiation. Nature 1982; 300: 362-6.
43. Lubet RA, McCarvill JT, Putman DL, Schwartz JL, Schechtman LM. Effect of 3-aminobenzamide on the induction of toxicity and transformation by ethyl methanesulfonate and methylcholanthrene in BALB/3T3 cells. Carcinogenesis 1984; 5: 459-62.
44. Takahashi S, Nakae D, Yokose Y, Emi Y, Denda A, Mikami S, et al. Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats. Carcinogenesis 1984; 5: 901-6
45. Lubet RA, McCarvill JT, Schwartz JL, Putman DL, Schechtman LM. Effects of 3-aminobenzamide on the induction of morphologic transformation by diverse compounds in Balb/3T3 cells in vitro. Carcinogenesis 1986; 7: 71-5.
46. Jacobson EL, Smith JY, Nunbhakdi V, Smith DG. In: Althaus FR, Hilz H, Shall S, Eds, ADP-Ribosylation of Proteins. Berlin, Heidelberg, Springer-Verlag 1985; 277-283.
47. Kupper JH, Muller M, Jacobson MK, Tatsumi-Miyajima J, Coyle DL, Jacobson EL, et al. trans-dominant inhibition of poly(ADP-ribosyl) ation sensitizes cells against gamma-irradiation and N-methyl-N'-nitro-N-nitrosoguanidine but does not limit DNA replication of a polyomavirus replicon. Mol Cell Biol 1995; 15: 3154-63.
48. Tsutsumi M, Masutani M, Nozaki T, Kusuoka O, Tsujiuchi T, Nakagama H, et al. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity. Carcinogenesis 2001; 22: 1-3.
49. Menissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003; 22: 2255-63.
50. Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002; 277: 23028-36.
51. Augustin A, Spenlehauer C, Dumond H, Menissier-De Murcia J, Piel M, Schmit AC, et al. PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J Cell Sci 2003; 116: 1551-62.
52. Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M, et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999; 146: 917-28.
53. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998; 282: 1484-7.
54. Cook BD, Dynek JN, Chang W, Shostak G, Smith S. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol 2002; 22: 332-42.
55. Alvarez-Gonzalez R, Althaus FR. Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents. Mutat Res 1989; 218: 67-74.
56. Berger NA, Sikorski GW, Petzold SJ, Kurohara KK. Defective poly(adenosine diphosphoribose) synthesis in xeroderma pigmentosum. Biochemistry 1980; 19: 289-93.
57. Chang H, Sander CS, Muller CS, Elsner P, Thiele JJ. Detection of poly(ADP-ribose) by immunocytochemistry: A sensitive new method for the early identification of UVB- and H2O2-induced apoptosis in keratinocytes. Biol Chem 2002; 383: 703-8.
58. Jacobson EL, Antol KM, Juarez-Salinas H, Jacobson MK. Poly(ADP-ribose) metabolism in ultraviolet irradiated human fibroblasts. J Biol Chem 1983; 258: 103-7.
59. Vodenicharov MD, Ghodgaonkar MM, Halappanavar SS, Shah RG, Shah GM. Mechanism of early biphasic activation of poly(ADP-ribose) polymerase-1 in response to ultraviolet B radiation. J Cell Sci 2005; 118: 589-99
60. Epstein JH, Cleaver JE. 3-Aminobenzamide can act as a cocarcinogen for ultraviolet light-induced carcinogenesis in mouse skin. Cancer Res 1992; 52: 4053-4.
61. Farkas B, Magyarlaki M, Csete B, Nemeth J, Rabloczky G, Bernath S, et al. Reduction of acute photodamage in skin by topical application of a novel PARP inhibitor. Biochem Pharmacol 2002; 63: 921-32.
62. Stevnsner T, Ding R, Smulson M, Bohr VA. Inhibition of gene-specific repair of alkylation damage in cells depleted of poly(ADP-ribose) polymerase. Nucleic Acids Res 1994; 22: 4620-4.
63. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999; 260: 273-9.
64. Denu JM. Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases. Trends Biochem Sci 2003; 28: 41-8.
65. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-2.
66. Denu JM. Vitamin B3 and sirtuin function. Trends Biochem Sci 2005; 30: 479-83.
67. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
68. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-63.
69. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800.
70. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA 2000; 97: 5807-11.
71. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, Starai VJ, et al. A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci USA 2000; 97: 6658-63.
72. Liszt G, Ford E, Kurtev M, Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem 2005; 280: 21313-20.
73. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 Inhibits Glutamate Dehydrogenase and Opposes the Effects of Calorie Restriction in Pancreatic beta Cells. Cell 2006; 126: 941-54.
74. Haigis MC, Guarente LP. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-21.
75. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-5.
76. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. Embo J 2002; 21: 2383-96.
77. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 2006; 8: 1025-31.
78. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev 2006; 20: 1256-61.
79. Dryden SC, Nahhas FA, Nowak JE, Goustin AS, Tainsky MA. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 2003; 23: 3173-85.
80. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007; 26: 945-57.
81. Hallows WC, Albaugh BN, Denu JM. Where in the cell is SIRT3?-functional localization of an NAD+-dependent protein deacetylase. Biochem J 2008; 411: E11-3.
82. Cooper HM, Spelbrink JN. The human SIRT3 protein deacetylase is exclusively mitochondrial. Biochem J 2008; 411: 279-85.
83. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem 2005; 280: 13560-7.
84. Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol 2003; 38: 1065-70.
85. Bellizzi D, Dato S, Cavalcante P, Covello G, Di Cianni F, Passarino G, et al. Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics 2007; 89: 143-50.
86. Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 2007; 21: 920-8.
87. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and Regulation Mechanisms for the Human Mitochondrial Sirtuins Sirt3 and Sirt5. J Mol Biol 2008; 382(3): 1790-801.
88. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-35.
89. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11: 437-44.
90. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124: 315-29.
91. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev 2006; 20: 1075-80.
92. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: The 'magnificent seven', function, metabolism and longevity. Ann Med 2007; 39: 335-45.
93. Blander G, Bhimavarapu A, Mammone T, Maes D, Elliston K, Reich C, et al. SIRT1 Promotes Differentiation of Normal Human Keratinocytes. J Invest Dermatol 2008; [Epub ahead of print].
94. Saunders LR, Verdin E. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26: 5489-504.
95. Jacobson EL, Smith JY, Mingmuang M, Meadows R, Sims JL, Jacobson MK. Effect of nicotinamide analogues on recovery from DNA damage in C3H10T1/ 2 cells. Cancer Res 1984; 44: 2485-92.
96. Jacobson EL, Shieh WM, Huang AC. Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. Mol Cell Biochem 1999; 193: 69-74.
97. Jacobson EL, Giacomoni PU, Roberts MJ, Wondrak GT, Jacobson MK. Optimizing the energy status of skin cells during solar radiation. J Photochem Photobiol B 2001; 63: 141-7.
98. Kirkland JB. Niacin and carcinogenesis. Nutr Cancer 2003; 46: 110-8
99. Gensler HL, Williams T, Huang AC, Jacobson EL. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer 1999; 34: 36-41.
100. Spronck JC, Kirkland JB. Niacin deficiency increases spontaneous and etoposide-induced chromosomal instability in rat bone marrow cells in vivo. Mutat Res 2002; 508: 83-97.
101. Zhang JZ, Henning SM, Swendseid ME. Poly(ADP-ribose) polymerase activity and DNA strand breaks are affected in tissues of niacin-deficient rats. J Nutr 1993; 123: 1349-55.
102. Spronck JC, Nickerson JL, Kirkland JB. Niacin deficiency alters p53 expression and impairs etoposide-induced cell cycle arrest and apoptosis in rat bone marrow cells. Nutr Cancer 2007; 57: 88-99.
103. Spronck JC, Bartleman AP, Boyonoski AC, Kirkland JB. Chronic DNA damage and niacin deficiency enhance cell injury and cause unusual interactions in NAD and poly(ADP-ribose) metabolism in rat bone marrow. Nutr Cancer 2003; 45: 124-31.
104. Boyonoski AC, Gallacher LM, ApSimon MM, Jacobs RM, Shah GM, Poirier GG, et al. Niacin deficiency increases the sensitivity of rats to the short and long term effects of ethylnitrosourea treatment. Mol Cell Biochem 1999; 193: 83-7.
105. Jacobson EL. Niacin deficiency and cancer in women. J Am Coll Nutr 1993; 12: 412-6.
106. Jacobson EL, Kim H, Kim M, Williams JD, Coyle DL, Coyle WR, et al. A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin. Exp Dermatol 2007; 16: 490-9.
107. Weitberg AB. Effect of nicotinic acid supplementation in vivo on oxygen radical-induced genetic damage in human lymphocytes. Mutat Res 1989; 216: 197-201.
108. Weitberg AB, Corvese D. Niacin prevents DNA strand breakage by adenosine deaminase inhibitors. Biochem Biophys Res Commun 1990; 167: 514-9.
109. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77: 574-9.
110. Damian DL, Halliday GM, Taylor CA, Barnetson RS. Ultraviolet radiation induced suppression of Mantoux reactions in humans. J Invest Dermatol 1998; 110: 824-7.
111. Gensler HL. Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr Cancer 1997; 29: 157-62.
112. Damian DL, Patterson CR, Stapelberg M, Park J, Barnetson RS, Halliday GM. UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128: 447-54.
113. Landry J, Slama JT, Sternglanz R. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun 2000; 278: 685-90.
114. Li JH, Zhang J. PARP inhibitors. IDrugs 2001; 4: 804-12.
115. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54: 558-9.
116. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278: 9869-74.
117. Schaub A, Futterer A, Pfeffer K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol 2001; 31: 3714-25.
118. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003; 9: 352-5.
119. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303: 364-9.
120. Pike NB, Wise A. Identification of a nicotinic acid receptor: Is this the molecular target for the oldest lipid-lowering drug? Curr Opin Investig Drugs 2004; 5: 271-5.
121. Zhang Y, Schmidt RJ, Foxworthy P, Emkey R, Oler JK, Large TH, et al. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun 2005; 334: 729-32.
122. Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94-114.
123. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005; 115: 3634-40.
124. Draelos ZD, Jacobson EL, Kim H, Kim M, Jacobson MK. A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. J Cosmet Dermatol 2005; 4: 258-61.
125. Shah GM, Le Rhun Y., Sutarjone I., and Kirkland J.B. Niacin deficient SKH-1 mice are more susceptible to ultraviolet B radiation-induced skin carcinogenesis. Cancer Res 2002; 131: 3150S.
126. Lin SJ, Ford E, Haigis M, Liszt G, Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 2004; 18: 12-6.